Sanofi Is ‘Working On’ Resolving England’s Sarclisa Funding Concerns
NICE is not yet convinced that Sanofi’s recently approved combination treatment for relapsed or refractory multiple myeloma is value for money. Temporary funding under the Cancer Drugs Fund has also been ruled out.
You may also be interested in...
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.
Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.
The sponsors of Alsitek and quizartinib are hoping that new data generated for the drugs will resolve the concerns raised by the European Medicines Agency when it previously rejected the products for marketing in the EU.